Manchester Peptides catalogue profile
Tirzepatide
A dual GIP and GLP-1 receptor agonist associated with appetite, insulin and glucose-regulation pathways. Authorised prescription versions have established clinical uses, but unlicensed research material is not equivalent to an approved medicine.
Available catalogue formats
Choose the listed format
Prices shown are the current catalogue guide prices.Pen · 40 mg
Tirzepatide
Product information
A dual GIP and GLP-1 receptor agonist associated with appetite, insulin and glucose-regulation pathways. Authorised prescription versions have established clinical uses, but unlicensed research material is not equivalent to an approved medicine.
Evidence and sources at a glance
- Human evidence
- Multiple phase 3 trials and real-world use provide a much larger evidence base than is available for most catalogue peptides.
- Regulatory context
- Authorised tirzepatide medicines have approved indications and controlled supply routes; research material is not equivalent.
- NHS tirzepatide overview ↗UK public-health information on authorised use and safety context.
- SURMOUNT-1 trial ↗Peer-reviewed randomised human weight-management trial.
View supplied reference photograph
Plain-English identity
What is Tirzepatide?
Trials investigate the combined GIP and GLP-1 pathway effects on appetite, body weight, blood-glucose markers and wider cardiometabolic outcomes. Findings describe the products and populations studied.
Tirzepatide has established clinical evidence and authorised medical uses, but licensed treatment must use an approved prescription product under appropriate healthcare supervision. Unlicensed research material is not equivalent to an authorised medicine.
Evidence and sources at a glance
- Human evidence
- Multiple phase 3 trials and real-world use provide a much larger evidence base than is available for most catalogue peptides.
- Regulatory context
- Authorised tirzepatide medicines have approved indications and controlled supply routes; research material is not equivalent.
- NHS tirzepatide overview ↗UK public-health information on authorised use and safety context.
- SURMOUNT-1 trial ↗Peer-reviewed randomised human weight-management trial.
Third-party documentation
Certificates of Analysis
Reference reports concern the named submitted samples. A catalogue batch match has not been established; check the strength and source on each report.This should be treated as “not displayed”, not as evidence that analytical verification exists.
Browse all available COAsEvidence-led research guide
Go deeper into Tirzepatide
A dual GIP and GLP-1 receptor agonist used in authorised prescription medicines for type 2 diabetes and weight management.
Last reviewed 10 October 2026. Research and reference information only. This page does not provide dosing instructions, treatment recommendations or medical advice. Not for human or veterinary consumption.